Cardiff Oncology: Volatility Afoot With Onvansertib Update Near-Term

Stock Information for Cardiff Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cardiff Oncology Inc.

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Sidoti Events, LLC's Year-End Virtual Investor Conference
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.